Intravaginal drug delivery devices for the administration of 17ଲ-oestradiol precursors
Patent 5855906 Issued on January 5, 1999. Estimated Expiration Date: 
June 3, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 3, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3545439 Polymeric diffusion matrix containing estradiol diacetate Patent #: 4291014 InventorAssigneeApplicationNo. 849329 filed on 06/03/1997US Classes:424/433, Depot, pellet, matrix, or suppository424/422, Implant or insert424/430Vaginal, urethral, uterineExaminersPrimary: Brouillette, GabrielleAttorney, Agent or FirmInternational ClassA61F 013/00Foreign Application Priority Data1994-12-19 IEAbstractThe invention relates to an intravaginal drug delivery device for administration to a female mammal of certain 17ଲ-oestradiol precursors at a substantially constant rate for a period of at least three weeks. The 17ଲ-oestradiol precursor is a 17ଲ-oestradiol moiety in which the, or each, hydroxyl group of the 17ଲ-oestradiol moiety is blocked by a blocking group, which blocking group is readily removed from the 17ଲ-oestradiol in vivo. The 17ଲ-oestradiol precursor must have either a solubility in liquid silicone of not less than 0.1 mg/100 ml or a standard k value of not less than 0.1 μg/day/mm. The 17ଲ-oestradiol precursor must also have a solubility in distilled water of not less than 1 μg/100 ml. | |
